Web Access Research Portal

Researcher: Raspin, K (Dr Kelsie Raspin)

Fields of Research

Cancer genetics
Molecular targets
Respiratory diseases
Cancer diagnosis
Cancer cell biology
Gene expression (incl. microarray and other genome-wide approaches)
Predictive and prognostic markers
Genome structure and regulation
Cancer therapy (excl. chemotherapy and radiation therapy)
Medical genetics (excl. cancer genetics)
Medical biochemistry - nucleic acids
Solid tumours
Epigenetics (incl. genome methylation and epigenomics)

Research Objectives

Diagnosis of human diseases and conditions
Expanding knowledge in the biomedical and clinical sciences
Treatment of human diseases and conditions
Clinical health
Men's health
Efficacy of medications
Evaluation of health and support services

Career Best Publications

Research Publications

A rare variant in EZH2 is associated with prostate cancer risk; International Journal of Cancer
Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition; Prostate
Identification of a novel recurrent EEF2 gene amplification in familial prostate tumors; Genes, Chromosomes and Cancer
Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours; Scientific Reports
Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C; European Journal of Cancer
Preclinical interstitial lung disease in relatives of familial pulmonary fibrosis patients; Pulmonology

Research Projects

Advancing Precision Medicine for Men Diagnosed with Prostate Cancer; Perpetual Trustees (PT)
Applying innovative 'omics' technologies to identify key molecular drivers of metastatic bone tumours; Cancer Council of Tasmania (CCT)
Precision Medicine for Men with Prostate Cancer; Royal Hobart Hospital Research Foundation (RHHRF)
Understanding TMPRSS2:ERG gene fusions to improve prostate cancer diagnosis and treatment options; Cancer Council of Tasmania (CCT)
Explaining high risk gene/variant function in IPF

Research Candidate Supervision